While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kb upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of ...
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecu...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. While the majorit...
While mutations affecting protein-coding regions have been examined across many cancers, structural ...
© 2018 Elsevier Inc. Nearly all prostate cancer deaths are from metastatic castration-resistant pros...
We report the first combined analysis of whole-genome sequence, detailed clinical history, and trans...
PurposeProstate cancer is the second leading cause of male cancer deaths. Castration-resistant prost...
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, ef...
The increasing number of patients with sequenced prostate cancer genomes enables us to study not onl...
The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly unders...
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecu...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usuall...
Prostate tumours are highly variable in their response to therapies, but clinically available progno...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecu...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. While the majorit...
While mutations affecting protein-coding regions have been examined across many cancers, structural ...
© 2018 Elsevier Inc. Nearly all prostate cancer deaths are from metastatic castration-resistant pros...
We report the first combined analysis of whole-genome sequence, detailed clinical history, and trans...
PurposeProstate cancer is the second leading cause of male cancer deaths. Castration-resistant prost...
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, ef...
The increasing number of patients with sequenced prostate cancer genomes enables us to study not onl...
The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly unders...
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecu...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usuall...
Prostate tumours are highly variable in their response to therapies, but clinically available progno...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecu...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. While the majorit...